XORTX Therapeutics Inc. Common Stock
XRTXXORTX Therapeutics Inc. is a biopharmaceutical company focused on developing targeted therapies for kidney diseases, particularly those involving fluid and electrolyte imbalance. The company specializes in innovative treatments for conditions such as autosomal dominant polycystic kidney disease (ADPKD) and other related disorders, leveraging oral therapeutics to improve patient outcomes.
Company News
XORTX Therapeutics announced peer-reviewed research linking genetic factors to xanthine oxidase over-expression in gout and kidney disease, supporting the company's therapeutic approach. The company appointed Krysta Davies Foss to its board, corrected warrant issuance numbers from a recent $1.1M offering, and provided updates on its pending acqui...
XORTX Therapeutics has entered into a securities purchase agreement to sell 1,746,631 common shares at $0.63 per share, expecting to raise approximately $1.1 million for working capital and general corporate purposes.
XORTX Therapeutics received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, with a deadline of April 13, 2026. Failure to comply could result in delisting.
XORTX Therapeutics received a Nasdaq notification that its stock price has been below $1.00 for 30 consecutive business days, triggering a compliance review. The company has 180 calendar days to regain compliance and continue trading on the Nasdaq Capital Market.
The gout therapeutics market is experiencing steady growth with over 20 companies developing innovative treatments, driven by rising disease prevalence and increasing awareness of potential new therapies.
